GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Sefina ArifIria Gomez-TourinoYogesh KamraIrma Pujol-AutonellEmily HantonTimothy TreeDaisy MelandriCaroline HullDiane K WherrettCraig BeamBart O RoepAnna LorencMark PeakmanPublished in: Diabetologia (2020)
GAD-alum immunisation activates and propagates GAD-specific CD4 T cells with a distinctive bifunctional phenotype, the functional analysis of which might be important in understanding therapeutic responses.